ReproCELL Incorporated (4978) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2025, was ¥974 million, down 26.2% year-over-year, with an operating loss of ¥546 million and a net loss attributable to shareholders of ¥486 million, both significantly widening from the prior year.

• The company continues to invest in iPS cell and regenerative medicine R&D, with a focus on both short-term research support and long-term medical business growth.

Financial highlights

• Revenue: ¥974 million (down 26.2% year-over-year).

• Operating loss: ¥546 million (vs. ¥149 million loss in prior year period).

• Net loss attributable to shareholders: ¥486 million (vs. ¥104 million loss in prior year period).

• Cash and equivalents at period end: ¥2,635 million.

• R&D expenses for the period: ¥308 million.

Outlook and guidance

• The company aims for early profitability by strengthening core businesses, launching new initiatives, and accelerating regulatory approval for regenerative medicine products.